• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Adoptive cell therapy: Living drugs against cancer.过继细胞疗法:抗癌的活体药物。
J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20200377.
2
Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon.解决伊朗的癌症免疫疗法研究问题:过继细胞疗法即将面世。
Cytotherapy. 2018 Oct;20(10):1227-1237. doi: 10.1016/j.jcyt.2018.08.002. Epub 2018 Sep 26.
3
Adoptive cell transfer as personalized immunotherapy for human cancer.过继性细胞转移作为人类癌症的个性化免疫疗法。
Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967.
4
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.癌症免疫疗法:个性化策略与联合治疗方法
Mol Oncol. 2015 Dec;9(10):2043-53. doi: 10.1016/j.molonc.2015.10.009. Epub 2015 Oct 23.
5
Noninvasive imaging in cancer immunotherapy: The way to precision medicine.癌症免疫治疗中的无创影像学:迈向精准医学之路。
Cancer Lett. 2019 Dec 1;466:13-22. doi: 10.1016/j.canlet.2019.08.009. Epub 2019 Sep 6.
6
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.嵌合抗原受体修饰 T 细胞过继免疫疗法在癌症中的应用:现状与未来展望。
Front Biosci (Landmark Ed). 2019 Jun 1;24(7):1284-1315. doi: 10.2741/4780.
7
8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015--May 20-22, Vancouver, Canada.第八届加拿大癌症免疫治疗协会(CCIC)年会——2015年5月20日至22日,加拿大温哥华
Cancer Immunol Immunother. 2016 Feb;65(2):235-41. doi: 10.1007/s00262-015-1785-2. Epub 2016 Jan 12.
8
Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.乳腺癌的过继细胞免疫疗法:利用免疫细胞的力量。
J Leukoc Biol. 2024 Apr 29;115(5):866-881. doi: 10.1093/jleuko/qiad144.
9
CCR 20th Anniversary Commentary: Autologous T Cells-The Ultimate Personalized Drug for the Immunotherapy of Human Cancer.CCR 20周年评论:自体T细胞——人类癌症免疫治疗的终极个性化药物。
Clin Cancer Res. 2015 Dec 15;21(24):5409-11. doi: 10.1158/1078-0432.CCR-14-3131.
10
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.利用基因改造T细胞的癌症免疫疗法:从实验室到临床
Mol Immunol. 2015 Oct;67(2 Pt A):46-57. doi: 10.1016/j.molimm.2014.12.009. Epub 2015 Jan 13.

引用本文的文献

1
Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.肝细胞癌:发病机制、分子机制及治疗进展
Front Oncol. 2025 Apr 8;15:1526206. doi: 10.3389/fonc.2025.1526206. eCollection 2025.
2
Advances in nucleic acid-based cancer vaccines.基于核酸的癌症疫苗的进展。
J Biomed Sci. 2025 Jan 21;32(1):10. doi: 10.1186/s12929-024-01102-w.
3
Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors.一名银屑病患者接受抗程序性死亡-1治疗引发的细胞因子释放综合征:免疫检查点抑制剂的阴暗面
World J Clin Cases. 2024 Dec 16;12(35):6782-6790. doi: 10.12998/wjcc.v12.i35.6782.
4
Immunologic and Targeted Molecular Therapies for Chordomas: A Narrative Review.脊索瘤的免疫治疗和靶向分子治疗:一篇叙述性综述。
J Clin Med. 2024 Sep 24;13(19):5679. doi: 10.3390/jcm13195679.
5
Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.肝细胞癌概述:从分子角度到未来的治疗选择。
Cell Adh Migr. 2023 Dec;17(1):1-21. doi: 10.1080/19336918.2023.2258539. Epub 2023 Sep 19.
6
The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.肿瘤免疫微环境在软骨肉瘤中的作用:有前途的免疫治疗策略。
Front Immunol. 2023 Sep 1;14:1257254. doi: 10.3389/fimmu.2023.1257254. eCollection 2023.
7
AAV-mediated delivery of a Sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells.腺相关病毒介导的沉睡美人转座子和 mRNA 编码的转座酶的递送,用于治疗性免疫细胞的工程改造。
Nat Biomed Eng. 2024 Feb;8(2):132-148. doi: 10.1038/s41551-023-01058-6. Epub 2023 Jul 10.
8
The impact of microbially modified metabolites associated with obesity and bariatric surgery on antitumor immunity.与肥胖和减重手术相关的微生物修饰代谢物对抗肿瘤免疫的影响。
Front Immunol. 2023 May 16;14:1156471. doi: 10.3389/fimmu.2023.1156471. eCollection 2023.
9
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives.肝细胞癌的免疫治疗:现状与展望。
World J Gastroenterol. 2023 Feb 14;29(6):1054-1075. doi: 10.3748/wjg.v29.i6.1054.
10
Evolving therapeutic landscape of advanced hepatocellular carcinoma.晚期肝细胞癌不断演变的治疗格局。
Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11.

本文引用的文献

1
Chimeric antigen receptor T cell therapy comes to clinical practice.嵌合抗原受体 T 细胞疗法走向临床实践。
Curr Oncol. 2020 Apr;27(Suppl 2):S115-S123. doi: 10.3747/co.27.5283. Epub 2020 Apr 1.
2
Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.基因敲除 HLA I 类、II 类和 T 细胞受体使同种异体 T 细胞可用于过继性 T 细胞治疗。
Cancer Immunol Res. 2020 Jul;8(7):926-936. doi: 10.1158/2326-6066.CIR-18-0508. Epub 2020 Apr 22.
3
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.FDA 批准帕博利珠单抗用于生物标志物定义的疾病的意义和影响。
J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.
4
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.针对抗原呈递细胞中的 LAG-3 和 PD-1 以增强 T 细胞的激活。
Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. eCollection 2018.
5
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.用于B细胞肿瘤的嵌合抗原受体T细胞:为您选择合适的嵌合抗原受体
Curr Hematol Malig Rep. 2016 Oct;11(5):368-84. doi: 10.1007/s11899-016-0336-z.
6
Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.装甲嵌合抗原受体T细胞:利用细胞因子和促炎配体增强嵌合抗原受体T细胞的抗肿瘤功效。
Biochem Soc Trans. 2016 Apr 15;44(2):412-8. doi: 10.1042/BST20150291.
7
Treating cancer with genetically engineered T cells.用基因工程改造的 T 细胞治疗癌症。
Trends Biotechnol. 2011 Nov;29(11):550-7. doi: 10.1016/j.tibtech.2011.04.009. Epub 2011 Jun 12.
8
The biology of natural killer cells and implications for therapy of human disease.自然杀伤细胞的生物学特性及其对人类疾病治疗的意义。
J Hematother Stem Cell Res. 2001 Aug;10(4):451-63. doi: 10.1089/15258160152509073.

过继细胞疗法:抗癌的活体药物。

Adoptive cell therapy: Living drugs against cancer.

机构信息

Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20200377.

DOI:10.1084/jem.20200377
PMID:33227136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7686916/
Abstract

Immunotherapy has made a profound impact in the treatment of cancer in the last decade. Insights from the study of the intricate relationships between immune cells and cancer have led to the clinical development of strategies that redirect the power of the immune system to target and eliminate cancer. Today, immunotherapy represents a rapidly expanding and transformative force comprising multiple modalities.

摘要

在过去的十年中,免疫疗法在癌症治疗方面产生了深远的影响。对免疫细胞与癌症之间复杂关系的研究为临床开发策略提供了深入的见解,这些策略旨在引导免疫系统的力量来靶向和消除癌症。如今,免疫疗法代表了一种快速发展和变革的力量,包括多种模式。